23 May 2013
Keywords: Evolva, Arpida, Merger and acquisitions, iclaprim
Article | 11 September 2009
Privately-held Swiss biotechnology firm Evolva has entered into an agreement with fellow Switzerland-based Arpida to merge, thus rescuing the latter, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 September 2009
10 September 2009
© 2013 thepharmaletter.com